Donald Cousineau, DO
General Practice · Gaylord, MINPI 1841485133
Payments from drug & device makers
Across 347 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$788
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$534
- Novo Nordisk$429
- Amgen$408
- Grifols USA, LLC$384
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,079100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,033 |
| AbbVie(2 entities) | 48 | $788 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $534 |
| Novo Nordisk | 30 | $429 |
| Amgen | 24 | $408 |
| Grifols USA, LLC | 19 | $384 |
| Pfizer | 15 | $365 |
| Xeris Pharmaceuticals, Inc. | 12 | $241 |
| Lilly USA, LLC | 10 | $165 |
| Sanofi-aventis U.S. LLC | 7 | $146 |
| Exact Sciences | 7 | $143 |
| GSK | 9 | $142 |
| Teva Pharmaceuticals USA, Inc. | 8 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $124 |
| Sunovion Pharmaceuticals Inc. | 17 | $121 |
| Axsome Therapeutics, Inc. | 4 | $98 |
| Merck | 6 | $92 |
| Johnson & Johnson | 6 | $84 |
| Novartis | 5 | $82 |
| Bayer | 4 | $76 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Antares Pharma, Inc. | 2 | $45 |
| Corcept Therapeutics | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Mylan Specialty L.p. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$6,079 in reported general payments places this provider in the 95th percentile of 3,051 general practice providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 77 | $81,248 |
| OzempicSemaglutide | 59 | $79,944 |
| EliquisApixaban | 83 | $76,961 |
| VraylarCariprazine Hcl | 39 | $57,832 |
| JardianceEmpagliflozin | 35 | $48,071 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $30,611 |
| MounjaroTirzepatide | 28 | $28,989 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $27,632 |
| XareltoRivaroxaban | 30 | $27,069 |
| MyrbetriqMirabegron | 31 | $20,287 |
| AptiomEslicarbazepine Acetate | 11 | $16,180 |
| CreonLipase/Protease/Amylase | 11 | $11,574 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,459 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,413 |
| LinzessLinaclotide | 12 | $8,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,033 | $108,880113 claims |
| Novo NordiskOzempic | $429 | $79,94459 claims |
| AbbVieVraylar, Creon, Linzess | $788 | $77,66662 claims |
| PfizerEliquis | $365 | $76,96183 claims |
| Boehringer IngelheimJardiance | $21 | $48,07135 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $142 | $41,06956 claims |
| Lilly USA, LLCMounjaro | $165 | $28,98928 claims |
| Johnson & JohnsonXarelto | $84 | $27,06930 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $20,28731 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $121 | $16,18011 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $146 | $9,41311 claims |
| MerckBelsomra | $92 | $5,66013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,051 general practice providers in Michigan.
Other general practice in Gaylord
- Anil PrasadTaylor$1.7M
- Sadeer DaoodDearborn$1.1M
- Shakib HalabuWest Bloomfield$1.1M
- Dennis FasbinderAnn Arbor$758K
- Christian GrothAnn Arbor$283K
- Kevin BoneSaginaw$125K
- David JulianiRochester Hills$106K
- Marie FluentAnn Arbor$106K
- Howard KormanRoyal Oak$93K
- Hans SchwarzSterling Heights$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.